MedTech Power Play: Phagenesis Taps Industry Giant for Global Push

NASHVILLE, Tenn. – April 29, 2026 – Phagenesis, a company at the forefront of treating swallowing disorders, has made a significant strategic move by appointing Dr. Stephen N. Oesterle, a towering figure in the medical technology world, to its Board of Directors. The announcement signals a deliberate acceleration of the company's U.S. and global expansion plans, leveraging Dr. Oesterle's formidable experience to navigate a critical growth phase.

Phagenesis is transitioning from an early-stage innovator to a commercial powerhouse, propelled by its Phagenyx® System—a novel neuromodulation therapy for dysphagia, or severe difficulty swallowing, a common and dangerous complication following a stroke. The appointment comes at what CEO Chad Hoskins calls an "inflection point," as the company aims to establish its technology as a new standard of care. Dr. Oesterle’s recruitment is seen by industry watchers as a major validation of Phagenesis’s technology and market potential, providing the strategic firepower needed to conquer a multi-billion-dollar market.

"Steve brings deep experience in medical technology across many applications, and he has experience from companies successfully navigating through critical stages of growth and value creation," said Oern Stuge MD, MBA, Chairman of the Board of Phagenesis. "He brings a rare combination of clinical insight, strategic perspective, and a track record of building category-defining technologies. His addition strengthens our Board and will be instrumental as Phagenesis continues to accelerate its next phase of U.S. growth and global expansion, executing on its long-term strategy."

The Oesterle Effect: A Track Record of Scaling Innovation

Dr. Oesterle is not just another board member; he is a strategic asset with a rare blend of clinical insight, corporate leadership, and venture capital acumen. For 14 years, he served as Senior Vice President for Medicine and Technology at Medtronic, a global leader in medical devices. As a member of the company's Executive Committee, he was a key architect of its long-term innovation strategy, overseeing technology R&D and guiding crucial corporate investments and acquisitions that shaped the company's trajectory.

His influence extends far beyond a single corporation. Dr. Oesterle currently serves on the boards of major public companies like Baxter International and Peijia Medical, and advises a who's-who of global investment firms, including EQT, Novo Holdings, and Temasek. This dual perspective—from inside the world’s largest MedTech companies and alongside the investors who fund the next generation—gives him a unique vantage point on what it takes to scale a breakthrough technology from a promising therapy to a global standard. This trend of seasoned executives from industry titans joining agile startups highlights a broader shift, where deep operational expertise is seen as the critical catalyst for turning innovation into market dominance.

"I am excited to join the Phagenesis Board at a pivotal moment in the company's evolution," said Dr. Oesterle. "Phagenesis has built a strong clinical foundation and is addressing a significant unmet need in patient care. The opportunity to improve outcomes for patients with severe dysphagia while reducing the cost and complexity for healthcare systems is compelling. I look forward to supporting the team as they scale the business and expand its impact globally."

Tackling a Costly and Dangerous Condition

The problem Phagenesis aims to solve is both widespread and severe. Dysphagia affects a staggering number of patients, with some studies indicating that up to 78% of individuals who suffer an acute stroke experience difficulty swallowing. This condition is far from a minor inconvenience; it is a primary driver of life-threatening complications like aspiration pneumonia, malnutrition, and dehydration.

The economic burden on the healthcare system is immense. Patients with dysphagia face hospital stays that are, on average, 76% longer than those without the condition. This translates into significantly higher costs, with one analysis showing an average increase of over $6,200 in inpatient costs per patient. The presence of dysphagia can add more than 40% to a patient's total healthcare costs and dramatically increases the likelihood of being discharged to a post-acute care facility rather than home.

Historically, treatment has focused on managing symptoms through dietary changes and compensatory strategies, with few therapies available to address the neurological root cause. Phagenesis's Phagenyx® System is designed to change that. It uses pharyngeal electrical stimulation (PES) to directly target the parts of the brain that control swallowing. By delivering targeted electrical pulses to the sensory nerves in the throat, the therapy aims to "rewire" and restore the brain's natural swallowing function, accelerating recovery.

This innovative approach recently received a powerful endorsement. The American Heart Association / American Stroke Association (AHA/ASA) updated its influential guidelines for acute ischemic stroke management to include PES as a beneficial treatment. The guidelines, which give PES a Class 2a recommendation, state that the therapy can be beneficial in reducing dysphagia severity and the risk of aspiration, providing a strong clinical tailwind for broader adoption.

Fueled by Capital and Clinical Validation

Dr. Oesterle’s appointment is the latest in a series of moves that underscore Phagenesis's aggressive growth strategy. In March 2024, the company announced the successful closure of a $42 million Series D financing round. The round was led by EQT Life Sciences and co-led by Sectoral Asset Management, with participation from new investors including British Patient Capital and Northern Gritstone.

The infusion of capital is earmarked specifically for building out the commercial infrastructure needed to penetrate the U.S. market, which is valued at over $1.5 billion for dysphagia management. The investment thesis of backers like EQT and Sectoral is clear: Phagenyx has the potential to become a paradigm-shifting standard of care that not only improves patient outcomes but also delivers significant cost savings to the healthcare system.

"Steve's addition comes at an inflection point for Phagenesis," said Chad Hoskins, the company's Chief Executive Officer. "We are transitioning from early commercialization to broader adoption, with strong clinical momentum and increasing recognition of the need to treat dysphagia at its neurological root cause. His experience building and scaling innovative medical technologies will be critical as we accelerate U.S. expansion, deepen clinical adoption, and establish Phagenyx as a standard of care."

With a clinically validated and guideline-recommended technology, substantial financial backing, and now the strategic guidance of one of the industry's most respected veterans, Phagenesis appears poised to transform the treatment landscape for one of medicine’s most challenging post-stroke complications.